Ruey‐Long Hong

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Anthony T.�C. Chan, Mow-Ming Hsu, Boon Cher Goh et al. · Journal of Clinical Oncology · 2005 · 289 citations · Full text

Translocation of Liposomes into Cancer Cells by Cell-Penetrating Peptides Penetratin and Tat: A Kinetic and Efficacy Study

Yun-Long Tseng, Jun‐Jen Liu, Ruey‐Long Hong · Molecular Pharmacology · 2002 · 238 citations

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

Roger B. Cohen, Jean‐Pierre Delord, Toshihiko Doi et al. · American Journal of Clinical Oncology · 2018 · 202 citations · Full text

Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T‐cell or T‐cell lymphoma

Chi‐Cheng Li, Hwei‐Fang Tien, Jih‐Luh Tang et al. · Cancer · 2004 · 184 citations · Full text